TABLE 2.
Basic features of the included studies.
| Study | Year | Country | Interventions and control | Number of patients (baseline) | Mean age (SD) | Duration | Outcomes reported | |
|---|---|---|---|---|---|---|---|---|
| Sall et al. (2020) | 2000 | United States | Restasis® | BID | 293 | 58.7 (13.9) | 6 months | ③④ |
| Artificial tears | BID | 292 | 59.9 (14.3) | |||||
| Stevenson et al. (2000) | 2000 | United States | Restasis® | BID | 33 | N/A | 12 weeks | ④ |
| Artificial tears | BID | 31 | N/A | |||||
| Perry et al. (2006) | 2006 | United States | Restasis® | BID | 16 | N/A | 3 months | ②③④ |
| Artificial tears | BID | 17 | N/A | |||||
| Willen et al. (2008) | 2008 | United States | Restasis® | BID | 22 | 44.0 (12.6) | 3 months | ①②③ |
| Artificial tears | BID | 22 | 42.2 (14.8) | |||||
| Kim et al. (2009) | 2009 | Korea | Restasis® | BID | 50 | 41.3 (9.7) | 3 months | ②③④ |
| Artificial tears | QID | 50 | 35.9 (8.5) | |||||
| Guzey et al. (2009) | 2009 | Turkey | Restasis® | BID | 32 | 61.5 (6.9) | 6 months | ①②③ |
| Vehicle | BID | 32 | 60.5 (8.2) | |||||
| Altiparmak et al. (2010) | 2010 | Turkey | Restasis® | BID | 25 | 41.0 (1.1) | 6 months | ②③④ |
| Artificial tears | BID | 48 | 40.9 (8.8) | |||||
| Chen et al. (2010) | 2010 | China | Restasis® | BID | 116 | 46.6 (11.1) | 8 weeks | ②③④ |
| Vehicle | BID | 117 | 46.0 (12.1) | |||||
| Rao (2010) | 2010 | China | Restasis® | BID | 41 | 47.5 (5.9) | 12 months | ①②③④ |
| Artificial tears | BID | 33 | 48.2 (6.3) | |||||
| Demiryay et al. (2011) | 2011 | Turkey | Restasis® +Artificial Tears | BID | 22 | 46.6 (12.3) | 4 months | ②③④ |
| Artificial Tears | QID | 20 | 44.3 (14.4) | |||||
| Prabhasawat et al. (2012) | 2012 | Thailand | Restasis® | BID | 36 | 48.1 (13.9) | 12 weeks | ①②④ |
| Artificial tears | BID | 34 | 55.0 (13.0) | |||||
| Kang et al. (2020) | 2019 | Korea | TJ Cyporin® | BID | 18 | 55.1 (13.5) | 12 weeks | ①②③④ |
| Restasis® | BID | 18 | 53.5 (9.7) | |||||
| Park et al. (2019) | 2019 | Korea | TJ Cyporin® | BID | 58 | N/A | 12 weeks | ①②③④ |
| Restasis® | BID | 58 | N/A | |||||
| Leonardi et al. (2016) | 2016 | 9 European countries | Ikervis® | QD | 154 | 60.8 (13.5) | 6 months | ①②③④ |
| Vehicle | QD | 91 | 62.1 (11.8) | |||||
| Baudouin et al. (2017) | 2017 | 6 European countries | Ikervis® | QD | 241 | 57.6 (12.9) | 6 months | ②④ |
| Vehicle | QD | 248 | 58.8 (12.7) | |||||
| Kim et al. (2017) | 2017 | Korea | Clacier® | BID | 34 | N/A | 12 weeks | ①②③④ |
| Restasis® | BID | 39 | N/A | |||||
| Tauber et al. (2018) | 2018 | United States | Cequa® | BID | 152 | 59.2 (14.6) | 12 weeks | ④ |
| Vehicle | BID | 152 | 59.3 (13.8) | |||||
| Goldberg et al. (2019) | 2019 | United States | Cequa® | BID | 371 | 58.4 (14.1) | 12 weeks | ④ |
| Vehicle | BID | 373 | 59.5 (14.7) | |||||
| Chen et al. (2019) | 2019 | China | Zirun® | BID | 119 | 46.3 (12.5) | 12 weeks | ①②③④ |
| Vehicle | BID | 115 | 45.0 (12.4) | |||||
| Wirta et al. (2019) | 2019 | The United States and Germany | CyclASol® | BID | 51 | 64.3 (10.7) | 16 weeks | ①④ |
| Restasis® | BID | 53 | 62.8 (11.9) | |||||
| Vehicle | BID | 52 | 61.3 (10.5) | |||||
| Sheppard et al. (2021) | 2021 | The United States and Germany | CyclASol® | BID | 162 | 61.5 (13.6) | 12 weeks | ③④ |
| Vehicle | BID | 166 | 61.3 (12.7) | |||||
Vehicle (the same ophthalmic emulsion formulation without cyclosporine); N/A, data not available; ① Ocular surface disease index (OSDI) score; ② Schirmer’s test (ST) with or without anesthesia; ③ Tear film break-up time (BUT); ④ Treatment-Emergent AEs (TEAEs).